Literature DB >> 19141441

A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus.

Christina L Hutson1, Victoria A Olson1, Darin S Carroll1, Jason A Abel1, Christine M Hughes1, Zachary H Braden1, Sonja Weiss1, Joshua Self1, Jorge E Osorio2, Paul N Hudson1, Michael Dillon3, Kevin L Karem1, Inger K Damon1, Russell L Regnery1.   

Abstract

Multiple monkeypox virus (MPXV) animal models have been discussed in previous studies, but no small animal models, nor most non-human primate models, demonstrated the protracted asymptomatic incubation phase seen in systemic human orthopoxvirus illness. Herein, we characterize a black-tailed prairie dog (PD) (Cynomys ludovicianus) model of infection, via intranasal and intradermal exposures, with the two MPXV clades. Daily observations of the animals were made (food consumption, general symptoms, disease presentation), while weights and virus evaluations (ocular, nasal, oropharyngeal, faeces, blood) were obtained/made every third day. Generalized rash became apparent 9-12 days post-infection for all animals. Individual animals demonstrated a range of symptoms consistent with human monkeypox disease. Measurable viraemias and excretas were similar for both clade-representative strains and persisted until at least day 21. Greater morbidity was observed in Congo Basin strain-challenged animals and mortality was observed only in the Congo Basin strain-challenged animals. The PD model is valuable for the study of strain-dependent differences in MPXV. Additionally, the model closely mimics human systemic orthopoxvirus disease and may serve as a valuable non-human surrogate for investigations of antivirals and next generation orthopoxvirus vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141441     DOI: 10.1099/vir.0.005108-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  51 in total

1.  Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.

Authors:  M S Keckler; D S Carroll; N F Gallardo-Romero; R R Lash; J S Salzer; S L Weiss; N Patel; C J Clemmons; S K Smith; C L Hutson; K L Karem; I K Damon
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.

Authors:  M Shannon Keckler; Mary G Reynolds; Inger K Damon; Kevin L Karem
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

3.  Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection.

Authors:  Ryan D Estep; Ilhem Messaoudi; Megan A O'Connor; Helen Li; Jerald Sprague; Alexander Barron; Flora Engelmann; Bonnie Yen; Michael F Powers; John M Jones; Bridget A Robinson; Beata U Orzechowska; Minsha Manoharan; Alfred Legasse; Shannon Planer; Jennifer Wilk; Michael K Axthelm; Scott W Wong
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

4.  Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Cynomys ludovicianus).

Authors:  Cynthia D Cary; Nicole L Lukovsky-Akhsanov; Nadia F Gallardo-Romero; Cassandram M Tansey; Sharon D Ostergaard; Willie D Taylor; Clint N Morgan; Nathaniel Powell; George W Lathrop; Christina L Hutson
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

5.  A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012.

Authors:  Scott Parker; R Mark Buller
Journal:  Future Virol       Date:  2013-02-01       Impact factor: 1.831

6.  Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.

Authors:  Donald F Smee
Journal:  Future Virol       Date:  2013-09       Impact factor: 1.831

7.  Protective properties of vaccinia virus-based vaccines: skin scarification promotes a nonspecific immune response that protects against orthopoxvirus disease.

Authors:  Amanda D Rice; Mathew M Adams; Scott F Lindsey; Daniele M Swetnam; Brandi R Manning; Andrew J Smith; Andrew M Burrage; Greg Wallace; Amy L MacNeill; Richard W Moyer
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

8.  Comparison of West African and Congo Basin monkeypox viruses in BALB/c and C57BL/6 mice.

Authors:  Christina L Hutson; Jason A Abel; Darin S Carroll; Victoria A Olson; Zachary H Braden; Christine M Hughes; Michael Dillon; Consuelo Hopkins; Kevin L Karem; Inger K Damon; Jorge E Osorio
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

9.  Comparison of monkeypox viruses pathogenesis in mice by in vivo imaging.

Authors:  Jorge E Osorio; Keith P Iams; Carol U Meteyer; Tonie E Rocke
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

10.  One more piece in the VACV ecological puzzle: could peridomestic rodents be the link between wildlife and bovine vaccinia outbreaks in Brazil?

Authors:  Jônatas S Abrahão; Maria Isabel M Guedes; Giliane S Trindade; Flávio G Fonseca; Rafael K Campos; Bruno F Mota; Zélia I P Lobato; André T Silva-Fernandes; Gisele O L Rodrigues; Larissa S Lima; Paulo C P Ferreira; Cláudio A Bonjardim; Erna G Kroon
Journal:  PLoS One       Date:  2009-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.